Evidence map›Paper›PMID 29016872›Full record

ArticleThe international journal of neuropsychopharmacology2017

Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia.

Manabu Kubota, Tomohisa Nagashima, Harumasa Takano, Fumitoshi Kodaka, Hironobu Fujiwara, Keisuke Takahata, Sho Moriguchi, Yasuyuki Kimura, Makoto Higuchi, Yoshiro Okubo and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Guanosine ameliorates positive symptoms of schizophreniaAmerican journal of translational research · 2021
    Article
  5. Effects of an Adenosine AFrontiers in neuroscience · 2021
    Article
  6. Review
  7. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2020
    Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Manabu KubotaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Tomohisa NagashimaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Harumasa TakanoDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Fumitoshi KodakaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Hironobu FujiwaraDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Keisuke TakahataDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Sho MoriguchiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yasuyuki KimuraDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Makoto HiguchiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yoshiro OkuboDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Hidehiko TakahashiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Hiroshi ItoDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Tetsuya SuharaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dopamine D2 receptors are reported to have high-affinity (D2High) and low-affinity (D2Low) states. Although an increased proportion of D2High has been demonstrated in animal models of schizophrenia, few clinical studies have investigated this alteration of D2High in schizophrenia in vivo. Methods: Eleven patients with schizophrenia, including 10 antipsychotic-naive and 1 antipsychotic-free individuals, and 17 healthy controls were investigated. Psychopathology was assessed by Positive and Negative Syndrome Scale, and a 5-factor model was used. Two radioligands, [11C]raclopride and [11C]MNPA, were employed to quantify total dopamine D2 receptor and D2High, respectively, in the striatum by measuring their binding potentials. Binding potential values of [11C]raclopride and [11C]MNPA and the binding potential ratio of [11C]MNPA to [11C]raclopride in the striatal subregions were statistically compared between the 2 diagnostic groups using multivariate analysis of covariance controlling for age, gender, and smoking. Correlations between binding potential and Positive and Negative Syndrome Scale scores were also examined. Results: Multivariate analysis of covariance demonstrated a significant effect of diagnosis (schizophrenia and control) on the binding potential ratio (P=.018), although the effects of diagnosis on binding potential values obtained with either [11C]raclopride or [11C]MNPA were nonsignificant. Posthoc test showed that the binding potential ratio was significantly higher in the putamen of patients (P=.017). The Positive and Negative Syndrome Scale "depressed" factor in patients was positively correlated with binding potential values of both ligands in the caudate. Conclusions: The present study indicates the possibilities of: (1) a higher proportion of D2High in the putamen despite unaltered amounts of total dopamine D2 receptors; and (2) associations between depressive symptoms and amounts of caudate dopamine D2 receptors in patients with schizophrenia.

Indexed as

AdultAntipsychotic AgentsApomorphineBrain MappingCorpus StriatumFemaleHumansMalePositron-Emission TomographyRacloprideRadioligand AssayRadiopharmaceuticalsReceptors, Dopamine D2SchizophreniaStatistics as TopicYoung AdultAntipsychotic AgentsApomorphineN-n-propylnorapomorphineRacloprideRadiopharmaceuticalsReceptors, Dopamine D2[11C]MNPA[11C]raclopridehigh affinityPETstriatum

Identifiers

PMID29016872
PMCPMC5737675
OpenAlexW2739073770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.